RENOVORX INC (RNXT) Stock Price, Quote, News and Overview
NASDAQ:RNXT - Nasdaq - US75989R1077 - Common Stock - Currency: USD
RNXT Quote, Performance and Key Statistics
RENOVORX INC
NASDAQ:RNXT (2/7/2025, 5:24:19 PM)
After market: 1.16 0 (0%)1.16
-0.3 (-20.55%)
The current stock price of RNXT is 1.16 USD. In the past month the price decreased by -12.12%. In the past year, price decreased by -27.04%.
RNXT Latest News and Analysis
What's going on in today's pre-market session
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
These stocks are moving in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
RenovoRx Announces Proposed Public Offering
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
RNXT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.83 | 336.82B | ||
| AMGN | AMGEN INC | 14.81 | 157.79B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 920.24 | 120.86B | ||
| GILD | GILEAD SCIENCES INC | 21.68 | 119.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.56 | 78.02B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.62B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.20B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 22.82B | ||
| BIIB | BIOGEN INC | 8.66 | 20.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.27 | 15.52B |
Related stock screener links
About RNXT
Company Profile
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapy platform to deliver chemotherapy. The company is headquartered in San Jose, California and currently employs 8 full-time employees. The company went IPO on 2021-08-17. The firm is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Company Info
RENOVORX INC
333 W Santa Clara St Ste 900
San Jose CALIFORNIA US
CEO: Shaun R. Bagai
Employees: 10
Company Website: https://renovorx.com/
Investor Relations: https://renovorx.com/investors/
Phone: 14088002649
RNXT FAQ
What is the stock price of RNXT?
The current stock price of RNXT is 1.16 USD.
What is the symbol for RENOVORX INC stock?
The exchange symbol of RENOVORX INC is RNXT and it is listed on the Nasdaq exchange.
On which exchange is RNXT stock listed?
RNXT stock is listed on the Nasdaq exchange.
Is RNXT a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for RNXT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of RNXT.
Does RNXT stock pay dividends?
RNXT does not pay a dividend.
What is the Price/Earnings (PE) ratio of RNXT?
RNXT does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.58).
What is the Short Interest ratio of RNXT stock?
The outstanding short interest for RNXT is 0.55% of its float.
RNXT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RNXT. When comparing the yearly performance of all stocks, RNXT is a bad performer in the overall market: 80.07% of all stocks are doing better.
RNXT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNXT. While RNXT seems to be doing ok healthwise, there are quite some concerns on its profitability.
RNXT Financial Highlights
Over the last trailing twelve months RNXT reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS decreased by 43.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -91.35% | ||
| ROE | -129.59% | ||
| Debt/Equity | 0 |
RNXT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to RNXT. The Buy consensus is the average rating of analysts ratings from 9 analysts.